ASP Isotopes Outlines Growth Strategy and Targets Over $300M EBITDA by 2031

ASP Isotopes (ASPI) provided an operational and strategic update during its inaugural Capital Markets Day, highlighting its transition from development to early commercialization in 2026. Management outlined its long-term growth potential and key milestones for the next 12 months across its nuclear medicine, electronics, helium, and nuclear fuels businesses.

Key Details

• Financial Target: The company is targeting more than $300 million of EBITDA in 2031.
• 12-Month Outlook: ASPI expects to increase revenues through liquid helium production (Phase 1 completion) and radiopharmacy growth, and begin its first commercial shipments from the stable isotope division.
• Corporate Strategy: The company continues to pursue separate public listings for its subsidiaries, Quantum Leap Energy and Noble Africa.